secwatch.observer — SEC 8-K summary
======================================

Issuer:     ANAPTYSBIO, INC (ANAB)
CIK:        0001370053
Form:       8-K
Filed at:   2026-07-30T20:05:15+00:00
Accession:  0001193125-26-326097
Event type: litigation
Sentiment:  neutral
Materiality: 0.30
Item codes: 7.01
LLM model:  deepseek-v4-flash:cloud@v2

AnaptysBio and Tesaro/GSK set post-trial briefing schedule in collaboration dispute
--------------------------------------------------------------------------------

- Trial held July 14-17, 2026 in Delaware Chancery Court over alleged breach of Collaboration Agreement.
- Court granted joint stipulation: AnaptysBio opening brief due Aug 21, 2026.
- Defendants' answering brief due Sep 25, 2026; AnaptysBio reply due Oct 9, 2026.
- Post-trial argument scheduled for October 20, 2026.
- No settlement or judgment announced; litigation remains ongoing.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1370053/000119312526326097/0001193125-26-326097-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1370053/000119312526326097/anab-20260728.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-326097

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer